Plasma Fibrinogen Level and the Risk of Major Cardiovascular Diseases and Nonvascular MortalityAnnika Rosengren, John Danesh, Sarah Lewington et al.|JAMA|2005Cited by 1.1k
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsDaniel I. Swerdlow, Rudi G. J. Westendorp, Niek Verweij et al.|The Lancet|2014Cited by 709
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controlsZheng Ye, John Danesh, Eugene H. C. Liu et al.|The Lancet|2006Cited by 409
Guidelines on fibrinogen assaysIan Mackie, Gordon Lowe, Steven Kitchen et al.|British Journal of Haematology|2003Cited by 294
Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosisFrits R. Rosendaal, Gordon Lowe, Martin Vessey et al.|British Journal of Haematology|2002Cited by 156